Latest on Ultrasound Renal Denervation

Published: 22 June 2022

  • Views:

    Views Icon 7346
  • Likes:

    Heart Icon 7
  • episode_image
    1h 4m 58s
    Part 7 | Session 1 ACC 2022 Symposium
    Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
  • episode_image
    59m 32s
    Part 7 | Session 2 TCT 2021 Symposium
    Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher
Average (ratings)
No ratings
Your rating

Overview

Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.

 

This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.

 

The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:

What you will learn:

  • How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
  • The clinical evidence supporting uRDN and its implications for the field of hypertension
  • The process for building a uRDN centre and therapy network

This page is designed for:

  • Interventional cardiologists
  • General cardiologists
  • Hypertension specialists
  • Nephrologists
  • Interventional radiologists

More from this programme

Part 4

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

Part 6

Patient Perspective & Provider Referral Development

Understand patient preference and referral development

Part 7

Discussion With Experts

Faculty Biographies

Michael Joner

Michael Joner

Head of the Preclinical Research

Dr Michael Joner MD completed his medical training at the University of Wuerzburg and spent 2004-2006 as a cardiovascular pathology fellow at the CVPath Institute. 

After returning to Germany, since 2007 Dr Joner has been Head of the Preclinical Research at the German Heart Centre in Munich, where he also completed his interventional cardiology residency. 

View full profile